

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 38005

Applicant:

Elisabeth DEFOSSA et al.

Confirmation No.

Appl. No.:

10/616,959

Examiner: Unassigned

Filing Date:

July 11, 2003

Art Unit: Unassigned

Title:

UREA- AND URETHANE-SUBSTITUTED ACYLUREAS, PROCESS

FOR THEIR PREPARATION AND THEIR USE

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56 and 37 CFR §1.97

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

English translations of the foreign-language documents may not be readily available; however, the absence of such translations does not relieve the PTO from its duty to consider the submitted documents (37 CFR §1.98 and MPEP §609).

TIMING/FEE

The instant Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) within three months from the filing date of the above-identified application, therefore, no fee is required in connection with its filing.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date: Oct 10, 2003

Customer No. 26633 HELLER EHRMAN WHITE & MCAULIFFE 1666 K Street, N.W., Suite 300

Washington, DC 20006

Telephone: (202) 912-2142 Facsimile: (202) 912-2020 Patricia D. Granados
Attorney for Applicant
Registration No. 33,683

Substitute for form 1449A/PTO

Complete if Known

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

TECH CENTER 1600/2900 **Application Number** Unassigned Filing Date July 11, 2003 First Named Inventor Elisabeth DEFOSSA et al. Group Art Unit Unassigned **Examiner Name** Unassigned

(use as many sheets as necessary)

Attorney Docket Number 38005-0178 Sheet of

				U.S. PATENT DOCU	MENTS	
Examiner Initials *	Cite No.¹	U.S. Patent Docum Number Kind Co (if know.	de ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01	6,221,633	B1	Ertl et al.	4/24/2001	
	A02	6,221,897	B1	Frick et al.	4/24/2001	
	A03	6,245,744	B1	Frick et al.	6/12/2001	
	A04	6,342,512	B1 '	Kirsch et al.	1/29/2002	
		,		••		
	•					

· · · · · · · · · · · · · · · · · · ·			F	OREIGN	PATENT DOCUMENTS			
		For	eign Patent Docum	ent		Date of	Pages, Columns, Lines, Where	
Examiner Initials*	Cite No. ¹	Office ³	Number⁴	Kind Code⁵ (if known)	Name of Patentee or Applicant of Cited Document	Publication of Cited Document MM-DD-YYYY	Relevant Passages or Relevant Figures Appear	Тв
0	A05	EP	0 221 847	A2	Ciba-Geigy AG	5/13/1987		
o	A06	wo	97/26265	A1	Novo Nordisk A/S	7/24/1997		
4	A07	wo	97/41097	A2	Dr. Reddy's Research Foundation	11/6/1997		
	A08	wo	98/08871	A1	Novo Nordisk A/S	3/5/1998		
۰	A09	wo	99/03861	A1	Novo Nordisk A/S	1/28/1999		
	A10	wo	99/15525	A1	Sanofi	4/1/1999		
~	A11	, WO	00/40569	A1	Alizyme Therapeutics Limited	7/13/2000		
_	م A12	wo	00/63208	A1	Novo Nordisk A/S	10/26/2000		
	A13 q	wo	00/64888	A1	Aventis Pharmaceuticals	11/2/2000		

Examiner Signature	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark hee if English language Translation is attached.

Substitute for form 1449A/PTO

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

office: U.S. DEPARTMENT OF COMINIMATION UNITED IN THE PROPERTY OF COMINIMATION UNITED IN THE PRO **Application Number** Filing Date First Named Inventor Group Art Unit **Examiner Name**

(use as many sheets as necessary)

of Sheet

Attorney Docket Number

U.S. PATENT DOCUMENTS U.S. Patent Document Name of Patentee or Date of Publication of Cited Document Pages, Columns, Lines, Where Relevant Examiner Cite No.1 Kind Code² Applicant of Cited Document Passages or Relevant Figures Appear Initials Number MM-DD-YYYY (if known)

				FOREIG	N PATENT DOCUMEN	ΓS		
Examiner Initials*	Cite No.1	For Office ³	eign Patent Doo Number⁴		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures	T ₆
	A23	EP	0462884	``	ADIR Et Compagnie	12/27/1991	Appear	
	, 20	'-	0.02004		, <u>2. 3011pagino</u>			
				_				
	Í							
			,					
•								

40.00	If the second to the second second to the second second to the second se	The part of the second	The Control of Control
Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.

O/h	L SCOOL	
E IE	Please bype a plus sign (+) inside this bo	×→ [+]
10.		

Substitute for form 1449A/PTO

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

for use through 10/31/2002. Co...
Office: U.S. DEPARTMENT OF COMmunition unless it contains a valid OMB control number.

Implete if Known
Unassigned
July 11, 2003
Elisabeth DEFOSS et accommodate and the control number.

Unassigned

Unassigned

Coloration unless it contains a valid OMB control number.

Elisabeth DEFOSS et accommodate and control number.

Coloration unless it contains a valid OMB control number.

Coloration unless it contains a valid OMB control number.

Coloration unless it contains a valid OMB control number.

Coloration unless it contains a valid OMB control number.

Coloration unless it contains a valid OMB control number.

Coloration unless it contains a valid OMB control number.

Coloration unless it contains a valid OMB control number.

Coloration unless it contains a valid OMB control number.

Coloration unless it contains a valid OMB control number.

Coloration unless it contains a valid OMB control number.

Coloration unless it contains a valid OMB control number.

Coloration unless it contains a valid OMB control number.

Coloration unless it contains a valid OMB control number. **Application Number** Filing Date First Named Inventor Group Art Unit **Examiner Name**

(use as many sheets as necessary)

2 of Attorney Docket Number Sheet

					U.S. PATENT DOCU	MENTS	
		U.S. P	atent Docume	nt	Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant
Examiner Initials *	Cite No. ¹	Number	Kind Code (if known)		Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
					٠.		

				FOREIG	N PATENT DOCUMENT	ΓS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆	
· · · · · · · · · · · · · · · · · · ·	A14 _B	wo	00/64876	A1	Aventis Pharmaceuticals	11/2/2000		
	A15	wo	00/66585	A1	Neurogen Corp.	11/9/2000		
	A16 •	wo	00/71549	A1	Knoll Aktiengesellschaft	11/30/2000		
٥	A17	wo	00/78312	A1	Merck & Co., Inc.	12/28/2000		
0	A18	wo	01/09111	A1	Eli Lilly & Co.	2/8/2001		
	A19	wo	01/83451	A1		11/8/2001		
0	A20	wo	01/85695	A1	Bristol-Myers Squibb	11/15/2001		
	A21 6	WO	01/91752	A1	Merck & Co., Inc.	12/6/2001		
	A22 a	DE	10142734	A1	Aventis Pharma Deutschland GmbH	3/27/2003		

Examiner Date Considered	Committee and the Committee of the Commi	the first of the state of the s	A property of the state of the		
Signature			Date Considered	,	Examiner Signature

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark hee if English language Translation is attached.

						>	
ype a	ı plus	sign	(+) inside	this	\rightarrow	יו

PTO/SB/08A	(08-00)
------------	---------

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

Application Number 10/616,959 July 11, 2003 Filing Date Elisabeth DEFOSSA et al. First Named Inventor **Group Art Unit** Unassigned

(use as many sheets as necessary)

Examiner Name Unassigned Attorney Docket Number 38005-0178 Sheet

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	A24	A. ASAKAWA et al., "Cocaine-Amphetamine-Regulated Transcript Influences Energy Metabolism, Anxiety and Gastric Emptying in Mice", Horm. Metab. Res., 2001, pp. 554-558, Vol. 33	
	A25	P. DRUECKES et al., "Photometric Microtiter Assay of Inorganic Phosphate in the Presence of Acid-Labile Organic Phosphates", Analytical Biochemistry, 1995, p. 173-177, Vol. 230	
	A26	H.D. ENGERS et al., "Kinetic mechanism of phosphorylase a. I. Initial velocity studies", Department of Biochemistry, University of Alberta, Edmonston 7, Alberta, January 12, 1970, pp. 746-754	
	A27	DANIEL W. LEE et al., "Leptin agonists as a potential approach to the treatment of obesity", Drugs of the Future, 2001, pp. 873-881, Vol. 26, No. 9	
	A28	HIROSHI OKADA et al., "Synthesis and Antitumor Activities of Prodrugs of Benzoylphenylureas", Chem. Pharm. Bull., 1994, pp. 57-61, Vol. 42, No. 1	
	A29	JAVIER SALVADOR et al., "Perspectives in the therapeutic use of leptin", Expert Opin. Pharmacother, 2001, 2001, pp. 1615-1622, Vol. 2, No. 10	
	A30	PRAVENN TYLE, "Iontophoretic Devices for Drug Delivery", Pharmaceutical Research, 1986, pp. 318-326, Vol. 3, No. 6	
	A31	H.J.F. ZUNFT et al., "Carob Pulp Preparation for Treatment of Hypercholesterolemia", Advances In Natural Therapy", September/October 2001, pp. 231-236, Vol. 18, No. 5	

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.